Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
1,263 stopped studies mapped to Lung Carcinoma and descendants · 91% state a reason
Over the 1,263 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00858364 | Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving… | Phase 3 | terminated | Mar 9, 2009 | Amgen | not stated | Not stated |
| NCT03661567 | Methylprednisolone After Split-course Chemoradiotherapy For Bulky Local Advanced… | Phase 2 | terminated | Sep 7, 2018 | Sun Yat-sen University | slow enrollment | Enrollment / accrual |
| NCT05481775 | Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy… | Phase 2 | withdrawn | Aug 1, 2022 | Sun Yat-sen University | Clincal decision based on previous results | Other (stated, no rule matched) |
| NCT03515629 | REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab… | Phase 3 | terminated | May 3, 2018 | Regeneron Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT05032352 | Predictive Assay for Decision Making in Adjuvant Therapy(PADMA) | — | terminated | Sep 2, 2021 | Insight Molecular Diagnostics | Non-safety related, reallocation of resources | Safety / toxicity |
| NCT03784599 | T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in…(TRAEMOS) | Phase 2 | terminated | Dec 24, 2018 | The Netherlands Cancer Institute | insufficient effectiveness | Other (stated, no rule matched) |
| NCT02437916 | Safety Study of AMG 228 to Treat Solid Tumors | Phase 1 | terminated | May 8, 2015 | Amgen | not stated | Not stated |
| NCT03430063 | A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer | Phase 2 | terminated | Feb 12, 2018 | Regeneron Pharmaceuticals | Business decision | Sponsor / business decision |
| NCT01266018 | Study of ADI-PEG 20 in Patients With Relapsed Sensitive or Refractory Small Cell Lung… | Phase 2 | terminated | Dec 24, 2010 | Ludwig Institute for Cancer Research | Lack of efficacy in Cohort 2; slow enrollment in Cohort 1 | Efficacy / futility |
| NCT04005144 | Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged… | Phase 1 | terminated | Jul 2, 2019 | University of California, San Francisco | Low Accrual | Enrollment / accrual |
| NCT04022876 | A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects… | Phase 1 | terminated | Jul 17, 2019 | Aileron Therapeutics, Inc. | With a favorable safety profile the difference between treatment groups for the primary composite… | Safety / toxicity |
| NCT04398199 | Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung… | Phase 2 | terminated | May 21, 2020 | Wake Forest University Health Sciences | Low accruals | Enrollment / accrual |
| NCT04861948 | IBI188 Combination Therapy in Solid Tumors | Phase 1 | terminated | Apr 27, 2021 | Innovent Biologics (Suzhou) Co. Ltd. | No signs of efficacy in solid tumors | Efficacy / futility |
| NCT05383001 | Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Durvalumab Plus… | Phase 2 | withdrawn | May 19, 2022 | AIO-Studien-gGmbH | Study was set-up in 2017, even though the protocol was adjusted, it was not possible to find… | Other (stated, no rule matched) |
| NCT04265534 | KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in…(KEAPSAKE) | Phase 2 | terminated | Feb 11, 2020 | Calithera Biosciences, Inc | Lack of Clinical Benefit | Efficacy / futility |
| NCT05116618 | Detection of Resistance Mechanisms in Cerebrospinal Fluid for EGFR-mutant, ALK- and… | — | withdrawn | Nov 11, 2021 | University of Colorado, Denver | Cancelled by Sponsor | Other (stated, no rule matched) |
| NCT00754364 | Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients | Phase 2 | terminated | Sep 18, 2008 | Armando Santoro, MD | low enrollment rate | Enrollment / accrual |
| NCT02967133 | A Study of Nivolumab +/- Nab-paclitaxel in Non-small Cell Lung Cancer | Phase 2 | terminated | Nov 18, 2016 | Alliance Foundation Trials, LLC. | Lack of enrollment | Enrollment / accrual |
| NCT04272203 | A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose… | Phase 1 | terminated | Feb 17, 2020 | AbbVie | Strategic considerations | Sponsor / business decision |
| NCT02706392 | Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies | Phase 1 | terminated | Mar 11, 2016 | Fred Hutchinson Cancer Center | Terminated due to slow accruals. | Enrollment / accrual |
| NCT00637624 | N-AcetylCysteine vs. Placebo to Prevent Neurotoxicity Induced by Platinum Containing…(NAC-PNP) | N/A | terminated | Mar 18, 2008 | Rijnstate Hospital | Unable to recruit enough patients | Enrollment / accrual |
| NCT04060342 | GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With… | Phase 1 | terminated | Aug 19, 2019 | GB006, Inc., a wholly owned subsidiary of Gossamer Bio, Inc. | No clear benefit of GB1275 was observed either as monotherapy or in combination with pembrolizumab. | Other (stated, no rule matched) |
| NCT03064854 | PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in… | Phase 1 | terminated | Feb 27, 2017 | Novartis Pharmaceuticals | Recruitment halted prematurely due to competitive landscape for lung cancer therapies | Enrollment / accrual |
| NCT03891173 | A Study of L-DOS47 in Combination With Vinorelbine/Cisplatin in Lung Adenocarcinoma | Phase 2 | terminated | Mar 26, 2019 | Helix BioPharma Corporation | Study was halted at this time due to other budgetary priorities. Completion of reporting has been… | COVID-19 / pandemic |
| NCT02400814 | MPDL3280A and Stereotactic Ablative Radiotherapy in Patients With Non-small Cell Lung… | Phase 1 | terminated | Mar 27, 2015 | Megan Daly, MD | Enrollment halted due to slow accrual. | Enrollment / accrual |
| NCT04069936 | Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in… | Phase 2 | terminated | Aug 28, 2019 | WindMIL Therapeutics | Resourcing | Other (stated, no rule matched) |
| NCT04560686 | Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell… | Phase 2 | terminated | Sep 23, 2020 | M.D. Anderson Cancer Center | Per PI Request | Other (stated, no rule matched) |
| NCT02856581 | Management of Tobacco Treatment Intervention in Reducing Surgical Complications in… | Phase 3 | terminated | Aug 5, 2016 | Alliance for Clinical Trials in Oncology | Slow accrual | Enrollment / accrual |
| NCT02325349 | PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During…(MLAPOCHI) | Phase 2 | terminated | Dec 25, 2014 | Assistance Publique - Hôpitaux de Paris | Change in protocol strategy | Sponsor / business decision |
| NCT04596033 | TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy | Phase 1 | terminated | Oct 22, 2020 | Genocea Biosciences, Inc. | Business reasons | Sponsor / business decision |
| NCT04210037 | Study of APG-1252 Plus Paclitaxel in Patients With Relapsed/Refractory Small Cell Lung… | Phase 1 / Phase 2 | terminated | Dec 24, 2019 | Ascentage Pharma Group Inc. | Sponsor decision | Sponsor / business decision |
| NCT03041181 | Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or… | Phase 2 | terminated | Feb 2, 2017 | Nasser Hanna, M.D. | Funder decision - lack of accrual | Enrollment / accrual |
| NCT03209128 | Cerebral Prophylactic Irradiation With Saving Hippocampus and Amygdala(IPC) | — | terminated | Jul 6, 2017 | Centre Francois Baclesse, Luxembourg | diffciculties to recruit patients and a lot of patients prematurely terminated | Enrollment / accrual |
| NCT03050060 | Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab,… | Phase 2 | terminated | Feb 10, 2017 | University of Washington | Terminated due to slow accrual | Enrollment / accrual |
| NCT03091491 | Study of Nivolumab Verses Nivolumab and Ipilimumab Combination in EGFR Mutant Non-small… | Phase 2 | terminated | Mar 27, 2017 | National Cancer Centre, Singapore | Slow recruitment due to general pessimism for immunotherapy in NSCLC, availability of alternative… | Enrollment / accrual |
| NCT03711422 | Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC | Phase 1 | terminated | Oct 18, 2018 | National Cancer Centre, Singapore | Decision to close the trial made due to low recruitment. | Enrollment / accrual |
| NCT04173325 | Feasibility and Safety Study of Nivolumab With Irinotecan for Small Cell Lung Cancer | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by the IRB 5/26/22 due to non-compliance | Other (stated, no rule matched) |
| NCT04173338 | Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer… | Phase 1 | terminated | Nov 21, 2019 | Augusta University | Closed by IRB on 3/28/22 | Other (stated, no rule matched) |
| NCT05022394 | Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in… | Phase 1 / Phase 2 | withdrawn | Aug 26, 2021 | M.D. Anderson Cancer Center | No participants Enrolled | Enrollment / accrual |
| NCT03904108 | Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have… | Phase 2 | terminated | Apr 4, 2019 | ROGER S KERESZTES MD | insufficient patient population to complete trial as planned | Other (stated, no rule matched) |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced… | Phase 1 / Phase 2 | terminated | Dec 11, 2017 | Sanofi | The study was stopped after interim analysis indicated that overall result was not sufficient to… | Efficacy / futility |
| NCT01487174 | KD019 Versus Erlotinib in Subjects With Stage IIIB/IV Non Small Cell Lung Cancer With… | Phase 3 | terminated | Dec 7, 2011 | Kadmon Corporation, LLC | Kadmon has made a business decision to terminate the study due to slow enrollment. Note the… | Safety / toxicity |
| NCT03655821 | Dose Individualization of Pemetrexed - IMPROVE-II(IMPROVE-II) | Phase 4 | terminated | Aug 31, 2018 | Radboud University Medical Center | 81 patients included, difficult inclusion and full inclusion would not change the results | Other (stated, no rule matched) |
| NCT04841538 | A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant… | Phase 1 / Phase 2 | withdrawn | Apr 12, 2021 | Elpiscience Biopharma, Ltd. | Sponsor's clinical development strategy adjustment | Sponsor / business decision |
| NCT02705404 | A Clinical Test for the Treatment of Multifocal Lung Cancers Using Genome Sequencing | — | terminated | Mar 10, 2016 | Mayo Clinic | Additional mechanisms/trials to enroll these patients exist and competed with the trial. | Enrollment / accrual |
| NCT03054038 | Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic… | Phase 1 | terminated | Feb 15, 2017 | Vanderbilt-Ingram Cancer Center | Low accrual | Enrollment / accrual |
| NCT00286169 | Amrubicin Study for Elderly Patients With Extensive-disease Small-cell Lung Cancer… | Phase 3 | terminated | Feb 3, 2006 | Sumitomo Pharma Co., Ltd. | not stated | Not stated |
| NCT05234606 | A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1… | Phase 1 / Phase 2 | withdrawn | Feb 10, 2022 | Silverback Therapeutics | Sponsor decision based on strategic re-alignment | Sponsor / business decision |
| NCT03754244 | A Phase I Study of TQ-B3456 on Tolerance and Pharmacokinetics | Phase 1 | terminated | Nov 27, 2018 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | The enrolment task cannot be gotten within the planned time.It mainly includes patients with… | Enrollment / accrual |
| NCT02460367 | Immunotherapy Combination Study in Advanced Previously Treated Non-Small Cell Lung Cancer | Phase 1 | terminated | Jun 2, 2015 | NewLink Genetics Corporation | Lack of enrollment and changing landscape of standard of care. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Nov 30, 2022source: clinicaltrials